Clincial Trials match your criteria
-
MERIT TrialMulti-center ESG Randomized Interventional Trial for the treatment of obesity
Multi-center ESG Randomized Interventional Trial (MERIT-Trial)
-
CONNECT-HF
CARE OPTIMIZATION THROUGH PATIENT AND HOSPITAL ENGAGEMENT CLINICAL TRIAL FOR HEART FAILURE—CONNECT-HF
-
tDNA Registry
Circulating tumor DNA exposure in peripheral blood using a novel process: A feasibility study
-
Study of nivolumab and relatilimab for untreated melanoma patients
A Randomized, Double-blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
-
Airway microbiome, nasal microRNA, and age 6-year asthma phenotypes in the MARC-35 cohort.
Airway microbiome, nasal microRNA, and age 6-year asthma phenotypes in the MARC-35 cohort.
-
Neoadjuvant therapy for abnormal HER2- Signaling
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
-
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial (enliGHten)
-
Continuation Study With Budesonide Oral Suspension for Adolescent and Adults
A Phase 3, Multicenter, Open-label Continuation Study with Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects with Eosinophilic Esophagitis (EoE)
-
Medial Epicondyle Fractures
Non-Operative Treatment Compared with Internal Fixation for Displaced Medial Humeral Epicondyle Fractures: A Multicenter Prospective Evaluation
-
Nivolumab/Nivolumab Plus Cisplatin, with radiation for SCCHN
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
